Proapoptotic and antiapoptotic proteins of the bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity

Journal of Immunotherapy

Volumn 38, Issue 3, 2015, Pages 116-126

  Bauer, Christian ^a   Hees, Claudia ^a   Sterzik, Alexander ^a   Bauernfeind, Franz ^a   Mak'Anyengo, Rachel ^a   Duewell, Peter ^a   Lehr, Hans Anton ^a   Noessner, Elfriede ^b   Wank, Rudolf ^c   Trauzold, Anna ^d   Endres, Stefan ^e   Dauer, Marc ^f   Schnurr, Max ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Immunotherapy Research Center   (Germany)

^d Institute of Pathology at Medizin Campus Bodensee ^*  (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f St Elisabeth Klinik   (Germany)

Author keywords

Bcl 2; chemotherapy; dendritic cells; gemcitabine; mitochondrial proteins; pancreatic carcinoma; siRNA; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GEMCITABINE; OVALBUMIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIMETABOLITE; CANCER VACCINE; DEOXYCYTIDINE; FAS ANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; CYTOTOXICITY; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD95; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMANS; IMMUNOTHERAPY; MICE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925623115     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000073     Document Type: Article

References (72)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcita-bine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
4. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23:3509-3516.
5. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
6. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol. 2007;34:347-353.
7. Kantoff PW, Higano CS, Shore NDE, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
8. Bauer C, Dauer M, Saraj S, et al. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother. 2011;60:1097-1107.
9. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63:4490-4496.
10. Bauer C, Bauernfeind F, Sterzik A, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut. 2007;56:1275-1282.
11. Bauer C, Sterzik A, Bauernfeind F, et al. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8 T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2014;63:321-333.
12. Mempel TR, Bauer CA. Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis. 2009;26:311-327.
13. Sun XM, Bratton SB, Butterworth M, et al. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem. 2002;277:11345-11351.
14. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7:1166-1173.
15. Waterhouse NJ, Sutton VR, Sedelies KA, et al. Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol. 2006;173:133-144.
16. Sutton VR, Vaux DL, Trapani JA. Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol. 1997;158: 5783-5790.
17. Goping IS, Barry M, Liston P, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity. 2003;18:355-365.
18. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med. 2000; 192:1403-1414.
19. Pinkoski MJ, Waterhouse NJ, Heibein JA, et al. Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway. J Biol Chem. 2001;276: 12060-12067.
20. Kurdow R, Schniewind B, Zoefelt S, et al. Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression. Langenbecks Arch Surg. 2005;390: 243-248.
21. Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer. 2004;109:182-188.
22. Fryer RA, Barlett B, Galustian C, et al. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisa-tion by the iMiD lenalidomide. Anticancer Res. 2011;31: 3747-3756.
23. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675-1687.
24. Scaffidi C, Schmitz I, Zha J, et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem. 1999;274:22532-22538.
25. Hogquist KA, Jameson SC, Heath WR, et al. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76: 17-27.
26. Hogquist KA, Jameson SC, Bevan MJ. The ligand for positive selection of T lymphocytes in the thymus. Curr Opin Immunol. 1994;6:273-278.
27. Schmidt T, Ziske C, Marten A, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 2003;63:8962-8967.
28. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
29. Jacobs C, Duewell P, Heckelsmiller K, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer. 2011;128:897-907.
30. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene. 2000;19:5477-5486.
31. Heckelsmiller K, Beck S, Rall K, et al. Combined dendritic cell-and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol. 2002;32:3235-3245.
32. Poeck H, Besch R, Maihoefer C, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med. 2008;14:1256-1263.
33. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57-67.
34. Trauzold A, Roder C, Sipos B, et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J. 2005;19:620-622.
35. Wang Z, Azmi AS, Ahmad A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of notch-1 signaling pathway. Cancer Res. 2009;69:2757-2765.
36. Martin AP, Park MA, Mitchell C, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol. 2009;76: 327-341.
37. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-681.
38. Raisova M, Hossini AM, Eberle J, et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001;117: 333-340.
39. Dauer M, Herten J, Bauer C, et al. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotox-icity induced by tumor lysate-pulsed dendritic cells. J Immun-other. 2005;28:332-342.
40. Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;97:458-465.
41. Correale P, Del Vecchio MT, La Placa M, et al. Chemo-therapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008;31:132-147.
42. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005; 175:820-828.
43. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 2005;16:55-76.
44. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett. 2013;332: 163-174.
45. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141-143.
46. Odoux C, Albers A. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. Vitam Horm. 2004;67:385-407.
47. Perkins C, Kim CN, Fang G, et al. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel-or etoposide-treated HL-60 cells. Cancer Res. 1998;58:4561-4566.
48. Perkins CL, Fang G, Kim CN, et al. The role of Apaf-1, caspase-9, and bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000; 60:1645-1653.
49. Christgen M, Schniewind B, Jueschke A, et al. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett. 2005;227:193-200.
50. Voskoboinik I, Trapani JA. Addressing the mysteries of perforin function. Immunol Cell Biol. 2006;84:66-71.
51. Voskoboinik I, Dunstone MA, Baran K, et al. Perforin: structure, function, and role in human immunopathology. Immunol Rev. 2010;235:35-54.
52. Law RH, Lukoyanova N, Voskoboinik I, et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature. 2010;468:447-451.
53. Lickliter JD, Cox J, McCarron J, et al. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. Br J Cancer. 2007;96:600-608.
54. Varadarajan S, Vogler M, Butterworth M, et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013;20:1475-1484.
55. Sutton VR, Sedelies K, Dewson G, et al. Granzyme B triggers a prolonged pressure to die in Bcl-2 overexpressing cells, defining a window of opportunity for effective treatment with ABT-737. Cell Death Dis. 2012;3:e344.
56. Ida H, Nakashima T, Kedersha NL, et al. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol. 2003;33: 3284-3292.
57. Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44:517-531.
58. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 1994;9:3049-3055.
59. Jansen B, Schlagbauer-Wadl H, Brown BD, et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med. 1998;4:232-234.
60. Anai S, Goodison S, Shiverick K, et al. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther. 2007;6:101-111.
61. Rosser CJ, Reyes AO, Vakar-Lopez F, et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1-6.
62. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer. 2003;97:1630-1638.
63. Ocker M, Neureiter D, Lueders M, et al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005;54:1298-1308.
64. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol. 2009;9:514-519.
65. Hon H, Rucker EB III, Hennighausen L, et al. bcl-xL is critical for dendritic cell survival in vivo. J Immunol. 2004;173: 4425-4432.
66. Sui H, Zhou M, Chen Q, et al. siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway. Nucleic Acids Res. 2014;42:583-598.
67. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541-552.
68. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-335.
69. Vremec D, Hansen J, Strasser A, et al. Maintaining dendritic cell viability in culture. Mol Immunol. 2015;63:264-267.
70. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.
71. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406-417.
72. Zhang HH, Pang M, Dong W, et al. miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 2014;31:1473-1479.